This CME series focuses on improving the overall management of patients with GI disease. Faculty experts provide education that is designed to strengthen clinician skill-sets needed to provide not only better patient care —via enhanced diagnosis and management strategies—but also to optimize patient outcomes through strategies that are meant to improve therapeutic adherence.
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
The Itch Is More Than Skin Deep: What the Changing Landscape of Primary Biliary Cholangitis (PBC) Means for Your Patients and You